# Beijing Kangleweishi Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beijing-kangleweishi-biotechnology-co

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: http://www.bj-klws.com
- Total disclosed funding: $2.2M
- Latest round: Series A (Sep 2, 2008)
- Investors on record: 1

## About

Based in Beijing, China, and founded in 2008, Beijing Kangleweishi Biotechnology Co., Ltd., trading under the name Heath Guard, provides a platform for the development of recombinant protein drugs. The company was listed under the name Kangle Guardian in National SME Share Transfer System in 2015. The company has established a new vaccine development technical team led by Chen Xiaojiang, Liu Yongjiang, Zhang Haijiang, and Wu Shuming. In August 2021, Beijing Kangleweishi Biotechnology Co., Ltd. raised CNY 1.02 billion in pre-IPO funding from new investors CCB International, Fuhai Jiuqian, Gaocheng Capital, Hongying Capital, Jiangxi Jemincare Group Co., Ltd., Yingke Private Equity, and Yufeng Capital.

The company's platform offers research and development of recombinant protein drugs and offers the development of HPV poly-vaccine. The platform helps to develop recombinant trivalent human papillomavirus (HPV) vaccine and a recombinant nine-valent HPV vaccine to prevent cervical cancer, a recombinant 15-valent HPV vaccine, a recombinant hand-foot-mouth disease (EV71/CoX A16 virus) vaccine, a recombinant Norovirus (NoV) vaccine and human parathyroid hormone (rh-PTH) and other biological products for prevention and treatment.

The company plans to expedite clinical trials of vaccines, expand its research and development to include hand-foot-and-mouth disease, norwalk virus, poliovirus, herpes zoster, influenza, and COVID-19, among others.

## Funding rounds

- Series A, Sep 2, 2008, $2.2M — Shenzhen Capital Real Estate Fund

## Investors

- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series A